Cortical Pathology in Vanishing White Matter

Vanishing white matter (VWM) is classified as a leukodystrophy with astrocytes as primary drivers in its pathogenesis. Magnetic resonance imaging has documented the progressive thinning of cortices in long-surviving patients. Routine histopathological analyses, however, have not yet pointed to cortical involvement in VWM. Here, we provide a comprehensive analysis of the VWM cortex. We employed high-resolution-mass-spectrometry-based proteomics and immunohistochemistry to gain insight into possible molecular disease mechanisms in the cortices of VWM patients. The proteome analysis revealed 268 differentially expressed proteins in the VWM cortices compared to the controls. A majority of these proteins formed a major protein interaction network. A subsequent gene ontology analysis identified enrichment for terms such as cellular metabolism, particularly mitochondrial activity. Importantly, some of the proteins with the most prominent changes in expression were found in astrocytes, indicating cortical astrocytic involvement. Indeed, we confirmed that VWM cortical astrocytes exhibit morphological changes and are less complex in structure than control cells. Our findings also suggest that these astrocytes are immature and not reactive. Taken together, we provide insights into cortical involvement in VWM, which has to be taken into account when developing therapeutic strategies.

[1]  K. Kuter,et al.  Beyond the GFAP-Astrocyte Protein Markers in the Brain , 2021, Biomolecules.

[2]  O. Elroy-Stein,et al.  The Energy Status of Astrocytes Is the Achilles’ Heel of eIF2B-Leukodystrophy , 2021, Cells.

[3]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[4]  Ya Chun Yu,et al.  Glutamine reliance in cell metabolism , 2020, Experimental & Molecular Medicine.

[5]  D. Downs,et al.  RidA Proteins Protect against Metabolic Damage by Reactive Intermediates , 2020, Microbiology and Molecular Biology Reviews.

[6]  Ulrike Winkler,et al.  Heterogeneity of Astrocytes in Grey and White Matter , 2019, Neurochemical Research.

[7]  Kyoko Watanabe,et al.  Astrocyte Subtype Vulnerability in Stem Cell Models of Vanishing White Matter , 2019, Annals of neurology.

[8]  S. van der Sluis,et al.  Vanishing white matter: deregulated integrated stress response as therapy target , 2019, Annals of clinical and translational neurology.

[9]  O. Elroy-Stein,et al.  eIF2B Mutations Cause Mitochondrial Malfunction in Oligodendrocytes , 2019, NeuroMolecular Medicine.

[10]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[11]  H. D. de Vet,et al.  Natural History of Vanishing White Matter , 2018, Annals of neurology.

[12]  M. S. van der Knaap,et al.  Vanishing white matter: a leukodystrophy due to astrocytic dysfunction , 2018, Brain pathology.

[13]  Maarten H. P. Kole,et al.  Axonal abnormalities in vanishing white matter , 2018, Annals of clinical and translational neurology.

[14]  O. Elroy-Stein Mitochondrial malfunction in vanishing white matter disease: a disease of the cytosolic translation machinery , 2017, Neural regeneration research.

[15]  M. S. van der Knaap,et al.  Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms , 2017, Acta Neuropathologica.

[16]  O. Elroy-Stein,et al.  Mutant eIF2B leads to impaired mitochondrial oxidative phosphorylation in vanishing white matter disease , 2017, Journal of neurochemistry.

[17]  Jüergen Cox,et al.  The MaxQuant computational platform for mass spectrometry-based shotgun proteomics , 2016, Nature Protocols.

[18]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[19]  M. Kamermans,et al.  Astrocytes are central in the pathomechanisms of vanishing white matter. , 2016, The Journal of clinical investigation.

[20]  E. Chang,et al.  Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse , 2016, Neuron.

[21]  M. Norenberg,et al.  Glutamine Synthetase: Role in Neurological Disorders. , 2016, Advances in neurobiology.

[22]  C. Proud,et al.  eIF2B: recent structural and functional insights into a key regulator of translation. , 2015, Biochemical Society transactions.

[23]  E. Hol,et al.  Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. , 2015, Current opinion in cell biology.

[24]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[25]  Arne V. Blackman,et al.  Neuronal morphometry directly from bitmap images , 2014, Nature Methods.

[26]  M. Nedergaard,et al.  White matter astrocytes in health and disease , 2014, Neuroscience.

[27]  C. Rose,et al.  Astrocyte glutamine synthetase: pivotal in health and disease. , 2013, Biochemical Society transactions.

[28]  Amin Derouiche,et al.  Glutamine Synthetase as an Astrocytic Marker: Its Cell Type and Vesicle Localization , 2013, Front. Endocrinol..

[29]  P. Scheffer,et al.  Hyaluronan accumulation and arrested oligodendrocyte progenitor maturation in vanishing white matter disease. , 2013, Brain : a journal of neurology.

[30]  Christian Giaume,et al.  Connexin-based intercellular communication and astrocyte heterogeneity , 2012, Brain Research.

[31]  R. Wek,et al.  Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism. , 2012, Advances in nutrition.

[32]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[33]  H. Prange,et al.  „Vanishing white matter disease“ , 2011, Der Nervenarzt.

[34]  S. Goldman,et al.  Defective Glial Maturation in Vanishing White Matter Disease , 2011, Journal of neuropathology and experimental neurology.

[35]  G. Scheper,et al.  Leukoencephalopathy With Vanishing White Matter: A Review , 2010, Journal of neuropathology and experimental neurology.

[36]  E. Aronica,et al.  GFAPδ in radial glia and subventricular zone progenitors in the developing human cortex , 2010, Development.

[37]  E. Marcotte,et al.  Global signatures of protein and mRNA expression levelsw , 2009 .

[38]  T. Strom,et al.  SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy , 2009, Nature Genetics.

[39]  S. Scherer,et al.  Gap Junctions Couple Astrocytes and Oligodendrocytes , 2008, Journal of Molecular Neuroscience.

[40]  M. Freire,et al.  Cajal's contributions to glia research , 2007, Trends in Neurosciences.

[41]  B. Ransom,et al.  Functional connexin “hemichannels”: A critical appraisal , 2006, Glia.

[42]  K. Büssow,et al.  Crystal structure of Homo sapiens protein hp14.5 , 2004, Proteins.

[43]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[44]  R. Auer,et al.  Embryonic intermediate filament, nestin, expression following traumatic spinal cord injury in adult rats , 2002, Neuroscience.

[45]  A. Bizzi,et al.  Cerebral White Matter Involvement in Children with Mitochondrial Encephalopathies , 2002, Neuropediatrics.

[46]  S. Naidu,et al.  Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter , 2002, Annals of neurology.

[47]  Rune R. Frants,et al.  Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter , 2001, Nature Genetics.

[48]  W. Brück,et al.  Myelinopathia centralis diffusa (vanishing white matter disease): Evidence of apoptotic oligodendrocyte degeneration in early lesion development , 2001, Annals of neurology.

[49]  C. Proud,et al.  Regulation of eukaryotic initiation factor eIF2B. , 2001, Progress in molecular and subcellular biology.

[50]  A. Hart,et al.  Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. , 1999, Radiology.

[51]  D. Rodriguez,et al.  Phenotypic variation in leukoencephalopathy with vanishing white matter. , 1999, Neurology.

[52]  C. Betsholtz,et al.  Intermediate Filament Protein Partnership in Astrocytes* , 1999, The Journal of Biological Chemistry.

[53]  D. Pham‐Dinh,et al.  Increased density of oligodendrocytes in childhood ataxia with diffuse central hypomyelination (CACH) syndrome: neuropathological and biochemical study of two cases , 1999, Acta Neuropathologica.

[54]  F. Gabreëls,et al.  A new leukoencephalopathy with vanishing white matter , 1997, Neurology.